Guerra-Pérez Natalia, Ramos Edurne, García-Hernández Marta, Pinto Celia, Soto Manuel, Martín M Elena, González Víctor M
Laboratory of aptamers, Servicio de Bioquímica-Investigación, IRYCIS-Hospital Ramón y Cajal, Madrid, Spain.
Aptus Biotech SL, Parque Científico de Madrid, Campus de Cantoblanco, Madrid, Spain.
PLoS One. 2015 Oct 12;10(10):e0140048. doi: 10.1371/journal.pone.0140048. eCollection 2015.
A poly (A)-binding protein from Leishmania infantum (LiPABP) has been recently cloned and characterized in our laboratory. Although this protein shows a very high homology with PABPs from other eukaryotic organisms including mammals and other parasites, exist divergences along the sequence that convert them in potential diagnostic markers and/or therapeutics targets. Aptamers are oligonucleotide ligands that are selected in vitro by their affinity and specificity for the target as a consequence of the particular tertiary structure that they are able to acquire depending on their sequence. Development of high-affinity molecules with the ability to recognize specifically Leishmania proteins is essential for the progress of this kind of study.
We have selected a ssDNA aptamer population against a recombinant 6xHIS-LiPABP protein (rLiPABP) that is able to recognize the target with a low Kd. Cloning, sequencing and in silico analysis of the aptamers obtained from the population yielded three aptamers (ApPABP#3, ApPABP#7 and ApPABP#11) that significantly bound to PABP with higher affinity than the naïve population. These aptamers were analyzed by ELONA and slot blot to establish affinity and specificity for rLiPABP. Results demonstrated that the three aptamers have high affinity and specificity for the target and that they are able to detect an endogenous LiPABP (eLiPABP) protein amount corresponding to 2500 L. infantum promastigotes in a significant manner. The functional analysis of the aptamers also revealed that ApPABP#11 disrupts the binding of both Myc-LiPABP and eLiPABP to poly (A) in vitro. On the other hand, these aptamers are able to bind and purify LiPABP from complex mixes.
Results presented here demonstrate that aptamers represent new reagents for characterization of LiPABP and that they can affect LiPABP activity. At this respect, the use of these aptamers as therapeutic tool affecting the physiological role of PABP has to be analyzed.
来自婴儿利什曼原虫的一种聚腺苷酸结合蛋白(LiPABP)最近已在我们实验室中克隆并鉴定。尽管该蛋白与包括哺乳动物和其他寄生虫在内的其他真核生物的聚腺苷酸结合蛋白具有非常高的同源性,但序列中存在差异,使其成为潜在的诊断标志物和/或治疗靶点。适体是寡核苷酸配体,由于其能够根据序列获得的特定三级结构,通过对靶标的亲和力和特异性在体外进行筛选。开发能够特异性识别利什曼原虫蛋白的高亲和力分子对于这类研究的进展至关重要。
我们针对重组6xHIS-LiPABP蛋白(rLiPABP)筛选了一个单链DNA适体群体,该群体能够以低解离常数识别靶标。对从该群体中获得的适体进行克隆、测序和计算机分析,得到了三种适体(ApPABP#3、ApPABP#7和ApPABP#11),它们与聚腺苷酸结合蛋白的结合亲和力明显高于原始群体。通过酶联免疫吸附测定(ELONA)和狭缝印迹分析这些适体,以确定其对rLiPABP的亲和力和特异性。结果表明,这三种适体对靶标具有高亲和力和特异性,并且它们能够以显著方式检测相当于2500个婴儿利什曼原虫前鞭毛体的内源性LiPABP(eLiPABP)蛋白量。适体的功能分析还表明,ApPABP#11在体外破坏了Myc-LiPABP和eLiPABP与聚腺苷酸的结合。另一方面,这些适体能够从复杂混合物中结合并纯化LiPABP。
此处呈现的结果表明,适体代表了用于鉴定LiPABP的新试剂,并且它们可以影响LiPABP的活性。在这方面,必须分析将这些适体用作影响聚腺苷酸结合蛋白生理作用的治疗工具的用途。